Evaluates p-Tau proteins and cytokines in Alzheimer’s disease, suggesting potential biomarkers for diagnosis.
To evaluate and validate SIMOA (Quanterix) assays for p-Tau217, p-Tau181, p-Tau205, p-Tau212, BD-Tau, and inflammatory cytokines (IL-1β, IL-6, IL-10, TNFα) using plasma from Alzheimer’s disease (AD) patients compared with healthy controls, and to assess correlative relationships among these biomarkers.
No takes yet. Share an insight, caveat, or question.
Chenna et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: